GET DAILY SIGNALSArcutis Biotherapeutics (ARQT) Delivers +45% Revenue Growth in Q3 2026
Key Takeaways
- Arcutis Biotherapeutics (ARQT) reported third quarter 2026 product revenue of $143.9 million, up 45% year over year from $99.2 million.
- Diluted earnings per share (EPS) came in at $0.06, below the consensus estimate of roughly $0.17, while revenue modestly topped expectations near $142 million.
- The company raised full-year 2026 net product sales guidance to $535 million–$545 million, up from the prior range of $525 million–$540 million.
- ZORYVE foam 0.3% was the largest growth driver at $75.1 million, followed by cream 0.3% at $37.8 million and cream 0.15% at $27.3 million.
- Operating cash flow stayed positive at $18.9 million, with cash and marketable securities of $259.8 million at quarter end.
- For more context, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover Trending AI Robots to see how AI-driven strategies are navigating current market conditions.
Earnings Context and Why It Matters
Arcutis Biotherapeutics (ARQT) is a commercial-stage dermatology company whose growth hinges almost entirely on the ZORYVE franchise of roflumilast-based topical treatments. Because the company only recently crossed into consistent profitability, each quarterly report is a direct test of whether prescription demand, reimbursement, and commercial spending are aligning. The third quarter of 2026 mattered because it showed whether summer seasonality would slow prescription momentum and whether heavy investment in a larger sales force and a celebrity awareness campaign would pressure the bottom line. The results confirmed robust top-line demand but also revealed the cost of aggressive commercial expansion, keeping investors focused on the balance between growth and margin. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Arcutis reported net product revenue of $143.9 million for the third quarter ended September 30, 2026, a 45% increase from $99.2 million a year earlier. Revenue slightly exceeded the consensus estimate of about $142 million. By product, ZORYVE topical foam 0.3% generated $75.1 million, cream 0.3% contributed $37.8 million, cream 0.15% added $27.3 million, and cream 0.05% brought in $3.7 million.
On the bottom line, the company posted net income of $8.8 million, or $0.07 basic and $0.06 diluted EPS, compared with net income of $7.4 million, or $0.06 per share, in the prior-year period. Diluted EPS of $0.06 fell short of the consensus estimate of roughly $0.17, largely reflecting sharply higher operating expenses. Selling, general and administrative (SG&A) costs rose to $99.6 million from $62.4 million, driven by marketing spend on the "Skin to Believe In" campaign and sales-force expansion, while research and development (R&D) expenses increased to $22.4 million. The company raised its full-year 2026 net product sales guidance to $535 million–$545 million. From what I see, the revenue beat shows solid underlying demand even as expenses climbed.
Market Reaction and Investor Sentiment
Reaction to the quarter was mixed. The top-line beat and raised full-year guidance reinforced the narrative of sustained ZORYVE demand, while the EPS miss highlighted the weight of elevated commercial spending. Investors appeared to interpret the results as evidence of healthy underlying demand offset by deliberate investment in long-term brand building. The appointment of a new chief commercial officer, effective November 4, 2026, added a leadership transition for the market to digest. Sentiment heading into the report had been broadly positive, with strong buy-side coverage and rising price targets, and the results largely preserved that confidence even as near-term profitability came in lighter than modeled. I’m watching this closely as the balance between growth and spending plays out.
Forward Outlook and Key Factors to Monitor
Looking ahead, the central question is whether ZORYVE can maintain its prescription trajectory while the company scales back on spending intensity over time. Management raised 2026 guidance, signaling confidence in continued momentum through the fourth quarter. Investors will watch whether gross-to-net (GTN) deductions — the discounts and rebates that reduce list prices to net revenue — keep improving toward the low-50s range, which would support margin expansion.
Regulatory catalysts also loom. A potential FDA (U.S. Food and Drug Administration) approval of ZORYVE cream 0.05% for infants as young as three months is expected in the first quarter of 2027, which could unlock a new pediatric patient population. Meanwhile, the company continues enrolling Phase 2 studies of ZORYVE foam 0.3% for hidradenitis suppurativa, with data expected in early 2027.
On the pipeline front, ARQ-234, a checkpoint agonist targeting the CD200 receptor for atopic dermatitis, has advanced into the multiple ascending dose portion of its Phase 1a/1b trial. Balancing these growth investments against profitability will be the key theme in coming quarters, and the market will be watching whether rising revenue ultimately translates into more consistent EPS beats. One thing that stands out is how the raised guidance supports the long-term story.
Using Tickeron’s AI Tools for Deeper Analysis
In my research process, I often turn to Tickeron’s tools to cross-check patterns and signals around names like ARQT. The AI Screener helps filter for similar setups in biotech and dermatology, while the AI Daily Buy/Sell Signals provides a quick view of momentum shifts. These resources fit naturally into reviewing quarterly results and spotting how the stock stacks up against peers without replacing core fundamental work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for ARQT shows an upward move is likely
ARQT's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 222 similar instances where the Aroon Indicator showed a similar pattern. In 198 of the 222 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARQT just turned positive on October 13, 2026. Looking at past instances where ARQT's MACD turned positive, the stock continued to rise in 39 of 44 cases over the following month. The odds of a continued upward trend are 89%.
ARQT moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ARQT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 82%.
Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARQT advanced for three days, in 249 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARQT moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In 28 of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at 88%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 58 of 69 cases where ARQT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARQT as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARQT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ARQT broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ARQT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARQT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.403) is normal, around the industry mean (3.051). ARQT's P/E Ratio (154.773) is considerably higher than the industry average of (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (7.435) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the development and commercialization of treatments for dermatological diseases.
Industry Biotechnology
Advertisement